Pioneering access for patients

Pioneering access for patients

Our Vision is to be the world’s leading and most valued generics and biosimilars company.

Download full report
Highlights

2024 by the numbers

Financial highlights1

Net sales to third parties2
USD 0.0 bn
+9% in constant currencies
Core EBITDA margin
0.0 %
+200 basis points
Management Free Cash Flow
USD 0.0 bn
+USD 1.0 billion
operating income
USD 0 m
+5% in constant currencies
CORE DILUTED EPS
USD 0.0
+28% in constant currencies
CORE ROIC
0.0 %
+250 basis points

Non-financial highlights3

Patient treatments
provided
0 m
Estimated number of patient
treatments provided
Savings delivered to US AND
EUROPEAN healthcare systems
USD 0 bn
Estimated savings delivered by
our key products
Social impact
 
USD 0 bn
Estimated impact delivered by
our key products annually4
  1. Non-IFRS measures are defined in Supplementary financial information section of the complete 2024 Integrated Annual Report.
  2. Net sales on this website and in our Integrated Annual Report refer systematically to net sales to third parties. In the first nine months of 2023, third-party sales excluded sales to our former parent. Post spin-off, sales to our former parent are reported as third-party sales.
  3. For definitions of our non-financial indicators, please see Sandoz.com/ESG_supplementary_disclosures_2024.
  4. Estimate from 2023. For details please see Sandoz.com/ESG_supplementary_disclosures_2024.
Letters to shareholders

Our Purpose enables us to drive performance and create value for our stakeholders.

Chairman - Giblert Ghostine
Chairman's letter

I am honored and pleased to introduce our second Integrated Annual Report, marking our first full year as an independent public company.

CEO - Richard Saynor
CEO STATEMENT

We have successfully completed our first full year as an independent company, with strong sales growth, clear margin progression to fund our future operations and consistent delivery on our strategic milestones.

2024 in review

A year of consistent
delivery

JANUARY 31
LAUNCH OF TYRUKO®
(natalizumab) in Germany as
first multiple sclerosis biosimilar.
MARCH 4
ACQUISITION OF CIMERLI®
Completion of acquisition of Cimerli
(biosimilar ranibizumab) from Coherus.
MARCH 5
US FDA APPROVAL OF
WYOST® / JUBBONTI®
for first and only
denosumab biosimilars.
FDA Approval
MARCH 21
OPENING OF NEW ANTIBIOTIC PRODUCTION FACILITY IN AUSTRIA
significantly increasing capacity.
Lab in Austria
MAY 22
EUROPEAN COMMISSION APPROVAL FOR WYOST® / JUBBONTI®
(first biosimilar denosumab).
JULY 1
US FDA APPROVAL OF PYZCHIVA®
(biosimilar ustekinumab).
JULY 25
EUROPEAN LAUNCH
OF PYZCHIVA®
(biosimilar ustekinumab).
AUGUST 12
US FDA APPROVAL
FOR ENZEEVU®
(biosimilar aflibercept).
NOVEMBER 15
EUROPEAN COMMISSION APPROVAL FOR AFQLIR®
(biosimilar aflibercept).
EU Approval
2024 Strategic milestones
Our strategy

Our strategy for creating shareholder and societal value

Three phases

In our second year as a standalone global leader, the Sandoz strategy remains fundamentally unchanged. We are building consistently on our solid foundations, with our strong leadership in home market Europe and strategic leadership ambitions in the key US market, to succeed in the long term. The strategy is evolving in three clear phases:

2024
2025
1

Leveraging our freedom as a
standalone company

2026
2027
2028
2

Establishing a world-class generics and
biosimilars company

2029
2030
3

Long-term leadership

Sandoz continues to optimize its product mix, with mid-term growth driven by a combination of increased volume in the base business and launches across generics and biosimilars. Together with the benefit from strong existing infrastructure and customer relationships, this generates attractive cash flow to support future investments.

Global reach

We produce quality generic and biosimilar medicines at scale

Patient treatments provided by region1
0m TREATMENTS PROVIDED GLOBALLY
Europe 0m 0%
North America 0m 0%
International 0m 0%
NET SALES BY REGION
USD 0.0 billion
Europe USD 0.0bn 0%
North America USD 0.0bn 0%
International USD 0.0bn 0%
  1. Calculated based on Sandoz treatments delivered (volumes sold); defined daily dose (according to the WHO); and treatment duration, based on Sandoz medical experts’ guidance.
ESG overview

Our ESG strategy has four pillars.

Driving impact and access to healthcare is at the core of what we do. Championing sustainability, empowering our people, and governing with integrity help us to advance our Purpose and integrate it into our strategy.

Driving Impact and Access

Pioneering access to generic and biosimilar medicines worldwide is central to what we do. We produce quality medicines at scale, making them more accessible and affordable, while partnering to accelerate the pace of change.

Championing Sustainability

We prioritize environmental sustainability, driving down our carbon footprint and preserving natural resources.

Empowering our People

People are central to our Purpose of pioneering access for patients. We foster a safe and diverse workforce and develop exceptional talent and an inclusive pioneering culture.

Governing with Integrity

We promote strong corporate governance that drives sound risk management, ethical behavior, and safe high-quality products.

Material topics
  • Impact & Access to Healthcare
  • Climate Change
  • Pollution (including AMR)
  • Supplier Management
  • Diversity, Equity & Inclusion
  • Corporate Culture
  • Health & Safety
  • Ethics, Corruption & Bribery
  • Product Quality & Safety
  • Data Privacy & Cybersecurity
Sustainable Development Goals (SDG) Commitments

Our top priority is to tackle unsustainable market conditions and practices that hinder access to vital generic medicines.“

Remo Illi Head Supply Chain Europe
Head Supply Chain Europe - Remo Illi